Author: Michael Pollastri

David Swinney, Ph D, is the chief executive officer of the Institute for Rare and Neglected Diseases Drug Discovery (i RND3). Dr. Swinney has devoted the majority of his career to analyzing and implementing drug discovery strategies that will increase the chance of success. Michael Pollastri holds the chair of chemistry and chemical biology at Northeastern University in Boston. He came to NEU from Pfizer, where he worked for 10 years as a research chemist. His research focus is discovery of new therapeutics for neglected tropical diseases.